Welcome to our dedicated page for Biodexa Pharmaceuticals Plc SEC filings (Ticker: BDRX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Biodexa Pharmaceuticals plc filings document a foreign private issuer that reports current information on Form 6-K and incorporates certain disclosures into Form S-8 and Form F-3 registration statements. The records cover preliminary annual results; pipeline disclosures for eRapa, MTX240 and tolimidone; clinical trial authorizations and enrollment updates; and material agreements such as the MTX240 license and collaboration arrangement.
Capital-structure disclosures describe ADS units, pre-funded warrants, Series L warrants, public-offering documents, ADR ratio matters and the relationship between ADSs and ordinary shares. Governance and corporate filings also cover executive and board appointments, exhibit-based press releases, and other foreign-issuer current reports tied to Biodexa’s biopharmaceutical development programs.
Biodexa Pharmaceuticals PLC is registering for resale up to 299,261,540,000 ordinary shares represented by 2,992,615 American Depositary Shares previously or potentially issued under a January 17, 2025 Purchase Agreement with C/M Capital Master Fund, LP.
This Post-Effective Amendment No. 2 updates the Form F-1 to include information from the Company’s Form 20-F for the year ended December 31, 2025 and updated selling shareholder disclosures. No new securities are being registered by this amendment; the prospectus covers resale of Depositary Shares issuable under the existing Equity Financing arrangement. The Company states it may receive up to $35.0 million gross under the Purchase Agreement depending on future sales, and that it will not receive proceeds from sales by the Selling Shareholder in this resale registration.
Biodexa Pharmaceuticals PLC files Post-Effective Amendment No. 2 to its Form F-1 to update the prospectus and continue the resale registration for 1,701,800,000 ordinary shares represented by 17,018 American Depositary Shares issuable upon exercise of Series J warrants. The company states we will not receive any proceeds from resale by the selling shareholders; proceeds from any cash exercise of the Series J warrants would be received by the company. Shares outstanding were 324,156,808,922 Ordinary Shares as of March 1, 2026. The prospectus notes the Depositary Shares trade on NASDAQ under BDRX and quotes a last reported closing price of $0.6603 on March 26, 2026.
Biodexa Pharmaceuticals PLC filed a Post-Effective Amendment No. 1 to its Form F-1 to register the issuance of Depositary Shares issuable upon exercise of remaining warrants from its December 2025 offering: up to 489,000 Depositary Shares (48,900,000,000 Ordinary Shares underlying Pre-Funded Warrants), up to 6,097,562 Depositary Shares (609,756,200,000 Ordinary Shares underlying Series L Warrants), and up to 152,439 Depositary Shares (15,243,900,000 Ordinary Shares underlying Placement Agent Warrants). No additional securities are being registered beyond those warrants; the amendment concerns only shares issuable on exercise of outstanding warrants. The prospectus states estimated net proceeds of approximately $20.0 million if all Pre-Funded and Series L Warrants are exercised for cash, and an additional $0.5 million if all Placement Agent Warrants are exercised for cash. The Company’s Depositary Shares trade on NASDAQ under BDRX, with a reported close of $0.6603 on March 26, 2026.
Biodexa Pharmaceuticals PLC filed Post-Effective Amendment No. 3 to a Form F-1 to update its registration statement and prospectus with 2025 annual report information and selling shareholder updates. The prospectus registers for resale 171,700,000 Ordinary Shares represented by 1,717 American Depositary Shares, issuable upon exercise of pre-funded warrants from a December 2023 private placement.
The company states it will receive no proceeds from these resale transactions and that all net proceeds will go to the selling shareholders; proceeds from cash exercises of the warrants would be payable to the company at an exercise price of $0.025 per Ordinary Share. Shares outstanding were 324,156,808,922 Ordinary Shares as of March 12, 2026.
Biodexa Pharmaceuticals PLC files Post-Effective Amendment No. 2 to a Form F-1 to update its resale prospectus. The registration covers an aggregate of 943,400,000 Ordinary Shares represented by 9,434 American Depositary Shares, each ADS representing 100,000 Ordinary Shares. The company will not receive proceeds from resale by the selling shareholders; proceeds from any cash exercise of warrants would be received by the company.
This amendment updates information including the Company’s Annual Report on Form 20-F for the fiscal year ended December 31, 2025 and selling shareholder details; no additional securities are being registered.
Biodexa Pharmaceuticals PLC filed Post-Effective Amendment No. 3 to its Form F-1 to update its prospectus and include information from its 2025 Form 20-F; no new securities are being registered. This amendment covers the resale of 109,800,000 Ordinary Shares represented by 1,098 Depositary Shares issuable upon exercise of Series D warrants.
The prospectus states the Company will receive no proceeds from resale by the selling shareholders; proceeds would go to those holders unless Series D warrants are exercised for cash. Each Depositary Share represents 100,000 Ordinary Shares. Ordinary Shares outstanding were 324,156,808,922 as of March 12, 2026.
Biodexa Pharmaceuticals PLC, a UK-based early-stage biopharmaceutical company, files its annual report for the year ended December 31, 2025. The group reports net losses of £6.25 million in 2025, £5.73 million in 2024 and £7.08 million in 2023, leading to an accumulated deficit of £155.67 million as of December 31, 2025.
Cash and cash equivalents were £8.53 million at year-end 2025, and management states that additional financing will be required before the third quarter of 2026, creating material uncertainty and substantial doubt about the company’s ability to continue as a going concern. Biodexa has a $35.0 million equity line of credit, under which it has sold $8.92 million of shares, but there is no assurance this will be sufficient.
The company has no recurring revenue and depends on successfully developing and licensing its product candidates, such as eRapa, MTX240 and tolimidone, in a highly competitive and heavily regulated environment. Biodexa also highlights prior material weaknesses in internal controls, complex capital structure changes, extensive shareholder approvals for new shares and significant clinical, regulatory, reimbursement and collaboration risks typical of small biotechnology issuers.
Biodexa Pharmaceuticals reported a 2025 net loss of £6.38 million, with cash and cash equivalents of £8.53 million at year-end and a net cash inflow of £6.87 million driven by £13.04 million of financing inflows.
Research and development spending fell 27% to £3.96 million as MTX110 was removed from the pipeline, while administrative costs rose 27% to £4.84 million, mainly from professional and financing-related fees and foreign exchange movements. The company is advancing eRapa into a registrational Phase 3 FAP trial, supporting a fully enrolled Phase 2 NMIBC study, progressing a Phase 2a T1D study for tolimidone, and has in-licensed MTX240 for GIST.
Management and auditors highlight a material uncertainty around going concern, as forecasts show additional funding will be required in Q3 2026 despite access to a $35.0 million equity line of credit, of which $26.08 million remained undrawn at 31 December 2025.